Literature DB >> 28868331

Mass Spectrometry-based in vitro Assay to Identify Drugs that Influence Cystine Solubility.

Neelanjan Bose1,2, Tiffany Zee1,2, Pankaj Kapahi1,2, Marshall L Stoller1.   

Abstract

Cystinuria is a rare genetic disorder characterized by recurrent, painful kidney stones, primarily composed of cystine, the dimer of the amino acid cysteine (Sumorok and Goldfarb, 2013). Using a mouse model of cystinuria, we have recently shown that administration of drugs that increase cystine solubility in the urine can be a novel therapeutic strategy for the clinical management of the disease (Zee et al., 2017). There is a large unmet need in the field for developing new drugs for cystinuria. To that end, here we describe a simple in vitro cystine solubility assay that is amenable for screening compounds to identify potential drugs that may influence cystine solubility. The assay includes preparing a supersaturated solution of cystine, incubating this solution with drug(s) of choice, and finally using high pressure liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) to quantify the amount of cystine precipitated under various conditions.

Entities:  

Keywords:  Cystine; Cystinuria; Drug screening; Kidney stones; L-cystine dimethyl ester; Mass spectrometry

Year:  2017        PMID: 28868331      PMCID: PMC5580967          DOI: 10.21769/BioProtoc.2417

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  10 in total

1.  Studies on the treatment of cystinuria.

Authors:  C E DENT; B SENIOR
Journal:  Br J Urol       Date:  1955-12

Review 2.  The CARI guidelines. Kidney stones: cystine stones.

Authors:  Gavin Becker
Journal:  Nephrology (Carlton)       Date:  2007-02       Impact factor: 2.506

3.  Cystic kidney disease in a patient with systemic toxicity from long-term D-penicillamine use.

Authors:  Farrukh M Koraishy; Robert A Cohen; Gary M Israel; Neera K Dahl
Journal:  Am J Kidney Dis       Date:  2013-06-21       Impact factor: 8.860

4.  Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design.

Authors:  Jeffrey D Rimer; Zhihua An; Zina Zhu; Michael H Lee; David S Goldfarb; Jeffrey A Wesson; Michael D Ward
Journal:  Science       Date:  2010-10-15       Impact factor: 47.728

Review 5.  Cystinuria.

Authors:  Aditya Mattoo; David S Goldfarb
Journal:  Semin Nephrol       Date:  2008-03       Impact factor: 5.299

6.  Urolithiasis in pediatric patients.

Authors:  D S Milliner; M E Murphy
Journal:  Mayo Clin Proc       Date:  1993-03       Impact factor: 7.616

Review 7.  Update on cystinuria.

Authors:  Nicola Sumorok; David S Goldfarb
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-07       Impact factor: 2.894

Review 8.  Cystinuria: current diagnosis and management.

Authors:  Panagiotis Saravakos; Vasiliki Kokkinou; Evangelos Giannatos
Journal:  Urology       Date:  2013-11-16       Impact factor: 2.649

Review 9.  The molecular bases of cystinuria and lysinuric protein intolerance.

Authors:  M Palacín; G Borsani; G Sebastio
Journal:  Curr Opin Genet Dev       Date:  2001-06       Impact factor: 5.578

10.  α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria.

Authors:  Tiffany Zee; Neelanjan Bose; Jarcy Zee; Jennifer N Beck; See Yang; Jaspreet Parihar; Min Yang; Sruthi Damodar; David Hall; Monique N O'Leary; Arvind Ramanathan; Roy R Gerona; David W Killilea; Thomas Chi; Jay Tischfield; Amrik Sahota; Arnold Kahn; Marshall L Stoller; Pankaj Kapahi
Journal:  Nat Med       Date:  2017-02-06       Impact factor: 53.440

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.